Using which, we identified osteopontin as a therapeutic target at the NVU in ischemic stroke and could demonstrate improvement of NVU cell function and BBB recovery upon OPN targeting, that was associated with improved survival and neurological outcome post-ischemic stroke (Fig. 9b). Here, SPP1 is linked to ischemic stroke.